Etentamig Trial Improved Multiple Myeloma Outcomes
The Phase 3 CERVINO trial showed significant progress against relapsed and refractory multiple myeloma.
Updated on Sept. 26, 2026 in Cancer
The phase 3 CERVINO trial demonstrated that etentamig significantly outperformed standard therapies for patients with relapsed and refractory multiple myeloma. Participants receiving the drug achieved a 74.0 percent overall response rate compared to 45.7 percent in the control group.
Why it matters
This trial highlights a potent new treatment option for patients who have already exhausted three major classes of standard myeloma therapies. By demonstrating a 60 percent risk reduction for disease progression or death, etentamig offers a potentially life-extending intervention for advanced cases.
The study utilized a randomized sample of 393 patients, with the treatment group showing a 40 percent complete response rate versus 7 percent for standard therapies. Reported side effects included a 28.3 percent rate of cytokine release syndrome and a 27.7 percent rate of grade 3/4 infections.
The players
Atrium Health Levine Cancer Institute
This medical institution serves as a leading hub for cancer research and was involved in the CERVINO trial investigations.
Wake Forest University
This academic institution provided research leadership and faculty expertise for the execution of the Phase 3 clinical trial.
The details
Patients in the CERVINO trial had received at least two prior lines of treatment and were triple-class exposed to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies. The etentamig regimen employed a single step-up dosing mechanism, with treatments administered every four weeks.
Timeline
September 2026: Data from the CERVINO trial were presented at an IMS meeting.
The Big Picture
This study follows the precedent set by the CERVINO trial to redefine treatment standards for triple-class-exposed multiple myeloma patients. The findings mark a departure from previous efficacy benchmarks, extending the viability of targeted therapies in high-risk patient populations.
This development offers a potential new path for patients who have not responded to traditional treatment combinations. Patients should discuss these clinical trial outcomes with their oncologists to determine if similar targeted therapies might be appropriate for their specific disease profile.
The takeaway
The successful trial results offer a promising alternative for patients struggling with advanced, drug-resistant multiple myeloma. These findings underscore the importance of ongoing clinical research in identifying more effective, targeted treatment regimens for complex cancers.
What happens next
Future research is already scheduled, including a phase 3 trial to evaluate etentamig combined with pomalidomide in patients experiencing early relapse. Additionally, a phase 2/3 study is currently exploring the use of etentamig-based therapies for less-fit patients diagnosed with the disease.
Further reading
For more information on the latest advancements in oncology, visit the Cancer section.
